CN101087603A - 新型药物组合物及其用于对抗不同形式的药物成瘾的用途 - Google Patents

新型药物组合物及其用于对抗不同形式的药物成瘾的用途 Download PDF

Info

Publication number
CN101087603A
CN101087603A CNA2005800448695A CN200580044869A CN101087603A CN 101087603 A CN101087603 A CN 101087603A CN A2005800448695 A CNA2005800448695 A CN A2005800448695A CN 200580044869 A CN200580044869 A CN 200580044869A CN 101087603 A CN101087603 A CN 101087603A
Authority
CN
China
Prior art keywords
pharmaceutical composition
amisulpride
composition according
dopaminergic
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800448695A
Other languages
English (en)
Chinese (zh)
Inventor
M·桑谢斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimaran Ltd
Original Assignee
Trimaran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimaran Ltd filed Critical Trimaran Ltd
Publication of CN101087603A publication Critical patent/CN101087603A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2005800448695A 2004-11-05 2005-11-07 新型药物组合物及其用于对抗不同形式的药物成瘾的用途 Pending CN101087603A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411810A FR2877573B1 (fr) 2004-11-05 2004-11-05 Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues
FR0411810 2004-11-05

Publications (1)

Publication Number Publication Date
CN101087603A true CN101087603A (zh) 2007-12-12

Family

ID=34953312

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800448695A Pending CN101087603A (zh) 2004-11-05 2005-11-07 新型药物组合物及其用于对抗不同形式的药物成瘾的用途

Country Status (9)

Country Link
US (1) US20080090895A1 (enExample)
EP (1) EP1814542A2 (enExample)
JP (1) JP2008519016A (enExample)
CN (1) CN101087603A (enExample)
AU (1) AU2005300424A1 (enExample)
CA (1) CA2586277A1 (enExample)
FR (1) FR2877573B1 (enExample)
RU (1) RU2007120707A (enExample)
WO (1) WO2006048560A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4129655A (en) * 1976-04-26 1978-12-12 Ciba-Geigy Corporation Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans
US4412999A (en) * 1982-04-14 1983-11-01 Merck & Co., Inc. Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
US6852716B2 (en) * 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease

Also Published As

Publication number Publication date
JP2008519016A (ja) 2008-06-05
CA2586277A1 (fr) 2006-05-11
RU2007120707A (ru) 2008-12-10
EP1814542A2 (fr) 2007-08-08
FR2877573A1 (fr) 2006-05-12
US20080090895A1 (en) 2008-04-17
WO2006048560A2 (fr) 2006-05-11
WO2006048560A3 (fr) 2006-07-06
FR2877573B1 (fr) 2007-02-02
AU2005300424A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
Herman et al. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal
Marona-Lewicka et al. Reinforcing effects of certain serotonin-releasing amphetamine derivatives
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
Gamberino et al. Neurobiology of tobacco smoking and other addictive disorders
KR101754045B1 (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법
CN105473135B (zh) 用于治疗精神症状的d-美沙酮
JP2005513033A (ja) 麻薬鎮痛剤を増強する方法及び組成物
Balerio et al. Baclofen analgesia: involvement of the GABAergic system
CN112218650A (zh) 肽及其用途
Arcaya et al. Dynorphin A increases substance P release from trigeminal primary afferent C-fibers
Herz et al. Neurochemical aspects of addiction: opioids and other drugs of abuse
US20110039834A1 (en) Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions
Su et al. Effects of intragastric agmatine on morphine-induced physiological dependence in beagle dogs and rhesus monkeys
CN101087603A (zh) 新型药物组合物及其用于对抗不同形式的药物成瘾的用途
Bhargava Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies
Deslandes et al. Drug dependence: neuropharmacology and management
Blanchet et al. Role of arachidonic acid in the regulation of the NMDA‐evoked release of acetylcholine in striatal compartments
Honkanen Modulation of Brain Dopaminergic neurotransmission in alcohol-preferring rats by alcohol and opioids
Ritz Molecular mechanisms of addictive substances
Bhargava and Abstinence Symptoms
Šulcová The role of spinal TRPV1 receptors in nociceptive signalling and the modulatory effect of chemokine CCL2 and µ-opioid receptor agonists
Herz et al. Neurochemical Aspects of Addiction: Opioids and Other
Stagliano Abstinence-induced withdrawal from fixed-ratio combinations of drugs and identification of amino acids in Planaria
Ho et al. Barbiturates
Beyer Role of the medial prefrontal cortex in cocaine sensitization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20071212

C20 Patent right or utility model deemed to be abandoned or is abandoned